Moderna's mRNA Flu Vaccine Approved by FDA for Adults 50 and Older

The U.S. FDA has approved Moderna's mFlusiva, an mRNA-based flu vaccine, for adults aged 50 and above. This marks the first mRNA preventive flu shot, offering a new option for seasonal influenza prevention. The approval includes accelerated authorization for those 65 or older, pending further study, representing a significant advancement in vaccine technology.